硫酸铁五水合物 | 142906-29-4

• 物质功能分类: 无机化工 - 无机盐 - 金属硫化物及硫酸盐
• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 过渡金属氧阴离子化合物
• 中文名称: 硫酸铁五水合物
• 英文名称: Iron(3+);trisulfate;pentahydrate
• CAS: 142906-29-4
• 化学式: Fe2H10O17S3
• 分子量: 490.0
• InChiKey: YHGPYBQVSJBGHH-UHFFFAOYSA-H

物化性质

• 沸点：
  The Anhydrous form decomposes (480ºC)
• 熔点：
  The Anhydrous form decomposes (480ºC)
• 溶解度：
  Soluble at room temperature
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -8.14
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  271
• 氢给体数：
  5
• 氢受体数：
  17

ADMET

代谢

硫酸铁的代谢相关的药代动力学研究尚未进行。

Pharmacokinetic studies related to the metabolism of ferric sulfate have not been performed.

来源:DrugBank

毒理性

• 毒性总结

硫酸铁已被证明是对眼睛、喉咙、胃肠和呼吸道有刺激作用的物质。

Ferric sulfate has been proven to be an irritating substance into the eye, throat, gastrointestinal and respiratory tract.

来源:DrugBank

毒理性

• 蛋白质结合

硫酸铁具有非常高的蛋白质结合特性，这一特性被认为是由于其酸性特性所致。[A32360]

Ferric sulfate presents very high protein binding properties, this property is thought to be due to its acidic profile.[A32360]

来源:DrugBank

吸收、分配和排泄

• 吸收

硫酸铁的吸收相关的药代动力学研究尚未进行。

Pharmacokinetic studies related to the absorption of ferric sulfate have not been performed.

来源:DrugBank

吸收、分配和排泄

• 消除途径

硫酸铁的消除相关的药代动力学研究尚未进行。

Pharmacokinetic studies related to the elimination of ferric sulfate have not been performed.

来源:DrugBank

吸收、分配和排泄

• 分布容积

硫酸铁的分布容积相关的药代动力学研究尚未进行。

Pharmacokinetic studies related to the volume of distribution of ferric sulfate have not been performed.

来源:DrugBank

吸收、分配和排泄

• 清除

硫酸铁的清除相关的药代动力学研究尚未进行。

Pharmacokinetic studies related to the clearance of ferric sulfate have not been performed.

来源:DrugBank

安全信息

• 海关编码：
  28332980

SDS

Name:	Iron(III)sulfate pentahydrate 97% Material Safety Data Sheet
Synonym:
CAS:	142906-29-4

Section 1 - Chemical Product MSDS Name:Iron(III)sulfate pentahydrate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
142906-29-4	Iron(III)sulfate pentahydrate	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Substance is noncombustible; use agent most appropriate to extinguish surrounding fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 142906-29-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: Fe2H10O17S3
Molecular Weight: 489.9338

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable.
Conditions to Avoid:
Incompatible materials, light, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Oxides of sulfur.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 142906-29-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Iron(III)sulfate pentahydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 142906-29-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 142906-29-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 142906-29-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate 、 氯仿 、 硫酸铁五水合物 、 sodium hydroxide 在 Sodium sulfate-III 作用下， 以 水 为溶剂， 以to give the title compound as a red amorphous glassy mass (4.22 g, 85% yield)的产率得到N-Ethyl-N-phenyl-5-chloro-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide iron (III) salt
  参考文献：
  名称：

  Compositions containing quinoline compounds

  摘要：

  一种稳定的固体制药组合物，基本上由公式（II）的盐的有效量和维持pH值优选在8以上的碱性反应成分或含有二价金属阳离子的盐，以及至少一种制药辅料组成；所述公式（II）的盐在常温下储存期间基本上稳定至少3年。一种稳定公式（II）的盐的过程。公式（II）的结晶盐及其制备过程。

  公开号：

  US07589208B2

文献信息

• Novel compounds
  申请人：Bjork Anders

  公开号：US20060004038A1

  公开（公告）日：2006-01-05

  A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R′ is hydrogen, C 1 -C 4 alkyl, C 1 -C 3 alkoxy; halogen, trifluoromethyl or OCH x F y , R″ is hydrogen, fluoro or chloro, that R″ being fluoro or chloro only when R′ is fluoro or chloro; R 3 is hydrogen or C 1 -C 5 alkyl R 4 is hydrogen, CH 2 OCOC(CH 3 ) 3 , pharmaceutically acceptable inorganic or organic cations, or COR 4 ′ wherein R 4 ′ is C 1 -C 5 alkyl, phenyl, benzyl or phenethyl; R 7 is methyl or ethyl; one of A and B is sulphur and the other is C—R 2 ; when A is S, R 2 is selected from hydrogen and methyl, with the proviso that R 2 is methyl only when R 3 is not hydrogen; and when B is S, R 2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.

  化合物的化学式为(I)，其中R为甲基、乙基、正丙基、异丙基、正丁基或烯丙基；R′为氢、C1-C4烷基、C1-C3烷氧基、卤素、三氟甲基或OCHxFy；R″为氢、氟或氯，当R′为氟或氯时，R″仅为氟或氯；R3为氢或C1-C5烷基；R4为氢、CH2OCOC(CH3)3、药学上可接受的无机或有机阳离子，或COR4′，其中R4′为C1-C5烷基、苯基、苄基或苯乙基；R7为甲基或乙基；A和B中的一个为硫，另一个为C-R2；当A为S时，R2从氢和甲基中选择，但R3不为氢时，R2仅为甲基；当B为S时，R2为氢；以及其任何互变异构体。一种包含化合物(I)的药物组合物，一种治疗恶性肿瘤或由自身免疫或病理性炎症引起的疾病的方法。
• New compositions containing quinoline compounds
  申请人：Jansson Karl

  公开号：US20050192315A1

  公开（公告）日：2005-09-01

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体药物组合物，基本上由公式（II）的盐的有效量和维持pH值在8以上的碱性反应成分或具有二价金属阳离子的盐以及至少一种药用辅料组成；所述公式（II）的盐在室温下储存至少3年期间基本上稳定。稳定公式（II）的盐的方法。公式（II）的结晶盐和制备该盐的方法。
• CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM
  申请人：Jansson Karl

  公开号：US20090232889A1

  公开（公告）日：2009-09-17

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体药物组合物，基本上包括公式（II）的晶体盐的有效量，以及维持pH值优选高于8的碱性反应组分或具有二价金属阳离子的盐；以及至少一种药物辅料；所述公式（II）的盐在室温下储存至少3年期间基本稳定。一种稳定公式（II）盐的方法。公式（II）的晶体盐及其制备方法。
• Crystalline salts of quinoline compounds and methods for preparing them
  申请人：Active Biotech AB

  公开号：US08314124B2

  公开（公告）日：2012-11-20

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体药物组成物，基本上包括公式（II）的晶体盐的有效量，以及维持pH值在8以上的碱性反应组分，或者是带有二价金属阳离子的盐；以及至少一种药用辅料；所述公式（II）的盐在室温下储存至少3年期间基本上是稳定的。一种稳定公式（II）的盐的方法。公式（II）的晶体盐和制备该盐的方法。